Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Zinzani PL, et al. Among authors: perotti a. Lancet Oncol. 2008 Apr;9(4):352-8. doi: 10.1016/S1470-2045(08)70039-1. Epub 2008 Mar 14. Lancet Oncol. 2008. PMID: 18342572 Clinical Trial.
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
Zinzani PL, Derenzini E, Pellegrini C, Rigacci L, Fabbri A, Gandolfi L, Argnani L, Casadei B, Pulsoni A, Gobbi M, Perotti A, Zaccaria A, Voso MT, Cabras MG, De Renzo A. Zinzani PL, et al. Among authors: perotti a. Ann Oncol. 2012 Mar;23(3):805-807. doi: 10.1093/annonc/mdr633. Epub 2012 Jan 27. Ann Oncol. 2012. PMID: 22287683 Free article. Clinical Trial. No abstract available.
Phase I/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-β monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors.
Bauer TM, Santoro A, Lin CC, Garrido-Laguna I, Joerger M, Greil R, Spreafico A, Yau T, Goebeler ME, Hütter-Krönke ML, Perotti A, Juif PE, Lu D, Barys L, Cremasco V, Pelletier M, Evans H, Fabre C, Doi T. Bauer TM, et al. Among authors: perotti a. J Immunother Cancer. 2023 Nov 29;11(11):e007353. doi: 10.1136/jitc-2023-007353. J Immunother Cancer. 2023. PMID: 38030303 Free PMC article. Clinical Trial.
Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility.
Rossin G, Zorzi F, De Pablos-Rodríguez P, Biasatti A, Marenco J, Ongaro L, Perotti A, Tulone G, Traunero F, Piasentin A, Gomez-Ferrer A, Zucchi A, Trombetta C, Simonato A, Rubio-Briones J, Bartoletti R, Ramírez-Backhaus M, Claps F. Rossin G, et al. Among authors: perotti a. Diagnostics (Basel). 2023 Jul 31;13(15):2543. doi: 10.3390/diagnostics13152543. Diagnostics (Basel). 2023. PMID: 37568905 Free PMC article. Review.
The Utility of Inflammatory Serum Markers in the Assessment of Perioperative Morbidity after Radical Cystectomy for Bladder Cancer.
Claps F, Rossin G, van Rhijn BWG, Mir MC, Mertens LS, Ongaro L, Traunero F, Iachimovsky AI, Piasentin A, Vedovo F, Perotti A, Tulone G, Zucchi A, Liguori G, Simonato A, Bartoletti R, Trombetta C, Pavan N. Claps F, et al. Among authors: perotti a. Medicina (Kaunas). 2023 May 11;59(5):926. doi: 10.3390/medicina59050926. Medicina (Kaunas). 2023. PMID: 37241158 Free PMC article.
Focus on the Use of Resveratrol in Bladder Cancer.
Zucchi A, Claps F, Pastore AL, Perotti A, Biagini A, Sallicandro L, Gentile R, Caglioti C, Palazzetti F, Fioretti B. Zucchi A, et al. Among authors: perotti a. Int J Mol Sci. 2023 Feb 26;24(5):4562. doi: 10.3390/ijms24054562. Int J Mol Sci. 2023. PMID: 36901993 Free PMC article. Review.
61 results